Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 361, Issue 2, 2000, Pages 181-186

  Grondin, Richard ^a   Tahar, Abdallah Hadj ^a   Doan, Van Diep ^a   Ladure, Philippe ^b   Bédard, Paul J ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

2 adrenoceptor; Dyskinesias; Idazoxan; L dopa; MPTP; Parkinson

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; IDAZOXAN; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; LOCOMOTION; MACACA; NONHUMAN; PARKINSON DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; GAMMA-AMINOBUTYRIC ACID; IDAZOXAN; LEVODOPA; MACACA FASCICULARIS; MOTOR ACTIVITY; MPTP POISONING; NOREPINEPHRINE; PARKINSON DISEASE; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 0033967659     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002109900167     Document Type: Article

References (40)

1. Antelman SM, Caggiula AR (1977) Norepinephrine-dopamine interactions and behavior. Science 195:646-653
2. Baraban JM, Aghajanian GK (1981) Noradrenergic innervation of serotonergic neurons in the dorsal raphe: demonstration by electron microscopic autoradiography. Brain Res 204:1-11
3. Bédard PJ, Gomez-Mancilla B, Blanchet PJ, Calon F, Grondin R, Gagnon C, Falardeau P, Goulet M, Morissette M, Rouillard C, Di Paolo T (1997) Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys. In: Olanow CW, Obeso JA (eds) Beyond the decade of the brain: dopamine agonists in early Parkinson's disease, vol 2. Wells Medical, Royal Tunbridge Wells, pp 101-113
4. 2 antagonist idazoxan in experimental parkinsonism: a pilot study. Mov Disord 12:114 (abstr)
5. 2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272:854-859
6. 1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 11:91-94
7. 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs. Brain Res Bull 26:627-631
8. Crossman AR (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 5:100-108
9. Dennis T, L'Heureux R, Carter C, Scatton B (1987) Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 241:642-649
10. 3H]rauwolscine. Brain Res 566:13-20
11. 2B-adrenoceptor subtypes in postmortem human brain. J Neurochem 58:1555-1560
12. 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. Psychopharmacology 96:521-527
13. Elsworth JD, Deutch AY, Redmond DE Jr, Sladek JR Jr, Roth RH (1990) MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate. Neurosci Lett 114:316-322
14. Gaspard P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B (1991) Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol 30:365-374
15. Geyer MA, Lee EHY (1984) Effects of clonidine, piperoxane and locus coeruleus lesion on the serotoninergic and dopaminergic systems in raphe and caudate nucleus. Biochem Pharmacol 33: 3399-3404
16. 2 agonist in MPTP-treated monkeys. Exp Neurol 117:185-188
17. Gomez-Mancilla B, Bédard PJ (1993) Effects of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427
18. 2-adrenergic receptors in L-dopa-induced dyskinesia in Parkinson's disease. Soc Neurosci 24:410 (abstr)
19. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14:744-753
20. Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology in Parkinson's disease. Adv Neurol 45:19-34
21. Jones BE, Moore RY (1977) Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res 127: 23-53
22. Lategan AJ, Marien MR, Colpaert FC (1990) Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res 523:134-138
23. L'Heureux R, Dennis T, Curet O, Scatton B (1986) Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J Neurochem 46:1794-1801
24. 2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 31:551-554
25. Marvidis M, Millan MJ, Colpaert FC (1990) Alpha-1 and alpha-2 antagonists differentially modulate d-amphetamine and apomorphine-induced rotation in substantia nigra-lesioned rats. Eur J Pharmacol 183:448 (abstr)
26. 2 agonists and antagonists. Brain Res 562:216-224
27. Mason ST, Fibiger HC (1979) Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol 187:703-724
28. Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR (1985) Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci Lett 61:195-200
29. Nicholas AP, Pieribone V, Hokfelt T (1993) Distribution of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol 328:575-594
30. Pifl C, Schingnitz G, Hornykiewicz (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44: 591-605
31. Raisman-Vozari R (1994) The locus coeruleus in Parkinson's disease. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson's disease. CRC Press, Boca Raton, pp 89-103
32. 2 antagonist, idazoxan, in patients with Parkinson's disease. Mov Disord 12:111 (abstr)
33. Regunathan S, Reis DJ (1996) Imidazoline receptors and their endogenous ligands. Ann Rev Pharmacol 36:511-544
34. Room P, Postema F, Korf J (1981) Divergent axon collaterals of rat locus coeruleus neurons: demonstration by a fluorescent double labeling technique. Brain Res 221:219-303
35. Ruzicka E, Ladure P, Roth J, Jech R, Mecir P, Peyro-Saint-Paul H (1997) Efficacy and safety of efaroxan, an alpha-2 adrenoceptor antagonist, in Parkinson' disease: an oral short-term study. Mov Disord 12:123 (abstr)
36. Scatton B, Zivkovic B, Dedek J (1980) Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther 215:494-499
37. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328
38. 2-adrenergic receptor subtype gene expression in rat brain. Mol Brain Res 21:133-149
39. Walter DS, Flockhart IR, Haynes MJ, Howlett DR, Lane AC, Burton R, Johnson J, Dettmar PW (1984) Effects of idazoxan on catecholamine systems in rat brain. Biochem Pharmacol 33: 2553-2557
40. Westlund KN, Sorkin LS, Ferrington DG, Carlton SM, Willcockson HH, Willis WD (1990) Serotoninergic and noradrenergic projections to the ventral posterolateral nucleus of the monkey thalamus. J Comp Neurol 295:197-207